Warning! GuruFocus detected
3 Severe warning signs
with CHY.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
ChemoMetec AS
ISIN : DK0060055861
Compare
Compare
Traded in other countries / regions
CHEMM.Denmark0DZ0.UKCHY.Germany IPO Date
2019-02-05Description
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 34.04 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.03 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 43 | |||||
Beneish M-Score | -2.1 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.2 | |||||
3-Year EBITDA Growth Rate | 13.3 | |||||
3-Year EPS without NRI Growth Rate | 15.2 | |||||
3-Year FCF Growth Rate | 0.9 | |||||
3-Year Book Growth Rate | 28.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 24.44 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.71 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 4.31 | |||||
9-Day RSI | 10.15 | |||||
14-Day RSI | 17.1 | |||||
3-1 Month Momentum % | 6.64 | |||||
6-1 Month Momentum % | 44.1 | |||||
12-1 Month Momentum % | 47.7 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.16 | |||||
Days Inventory | 1097 | |||||
Days Sales Outstanding | 54.86 | |||||
Days Payable | 121.92 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.02 | |||||
Dividend Payout Ratio | 0.41 | |||||
3-Year Dividend Growth Rate | 58.7 | |||||
Forward Dividend Yield % | 1.02 | |||||
5-Year Yield-on-Cost % | 0.87 | |||||
Shareholder Yield % | 0.95 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.07 | |||||
Operating Margin % | 45.77 | |||||
Net Margin % | 36.79 | |||||
FCF Margin % | 27.89 | |||||
ROE % | 30.52 | |||||
ROA % | 25.36 | |||||
ROIC % | 45.27 | |||||
3-Year ROIIC % | 20.95 | |||||
ROC (Joel Greenblatt) % | 115.17 | |||||
ROCE % | 38.92 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 37.27 | |||||
Forward PE Ratio | 31.41 | |||||
PE Ratio without NRI | 37.27 | |||||
Shiller PE Ratio | 96.57 | |||||
Price-to-Owner-Earnings | 66.4 | |||||
PEG Ratio | 1.39 | |||||
PS Ratio | 13.71 | |||||
PB Ratio | 10.54 | |||||
Price-to-Tangible-Book | 13.58 | |||||
Price-to-Free-Cash-Flow | 49.15 | |||||
Price-to-Operating-Cash-Flow | 35.76 | |||||
EV-to-EBIT | 32.2 | |||||
EV-to-EBITDA | 29.75 | |||||
EV-to-Revenue | 15.36 | |||||
EV-to-FCF | 55.69 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-Projected-FCF | 4.23 | |||||
Price-to-DCF (Earnings Based) | 1.06 | |||||
Price-to-DCF (FCF Based) | 1.4 | |||||
Price-to-Median-PS-Value | 1.09 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.85 | |||||
Price-to-Graham-Number | 4.74 | |||||
Price-to-Net-Current-Asset-Value | 17.58 | |||||
Price-to-Net-Cash | 47.77 | |||||
Earnings Yield (Greenblatt) % | 3.11 | |||||
FCF Yield % | 1.75 | |||||
Forward Rate of Return (Yacktman) % | 21.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ChemoMetec AS Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 61.599 | ||
EPS (TTM) (€) | 1.302 | ||
Beta | 1.83 | ||
3-Year Sharpe Ratio | -0.04 | ||
3-Year Sortino Ratio | -0.05 | ||
Volatility % | 53.27 | ||
14-Day RSI | 17.1 | ||
14-Day ATR (€) | 2.011017 | ||
20-Day SMA (€) | 68.155 | ||
12-1 Month Momentum % | 47.7 | ||
52-Week Range (€) | 37.56 - 82.6 | ||
Shares Outstanding (Mil) | 17.4 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ChemoMetec AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ChemoMetec AS Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
ChemoMetec AS Frequently Asked Questions
What is ChemoMetec AS(FRA:CHY)'s stock price today?
The current price of FRA:CHY is €52.55. The 52 week high of FRA:CHY is €82.60 and 52 week low is €37.56.
When is next earnings date of ChemoMetec AS(FRA:CHY)?
The next earnings date of ChemoMetec AS(FRA:CHY) is 2025-05-07.
Does ChemoMetec AS(FRA:CHY) pay dividends? If so, how much?
The Dividend Yield %  of ChemoMetec AS(FRA:CHY) is 1.02% (As of Today), Highest Dividend Payout Ratio of ChemoMetec AS(FRA:CHY) was 2.15. The lowest was 0.29. And the median was 0.77. The  Forward Dividend Yield % of ChemoMetec AS(FRA:CHY) is 1.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |